TORONTO, Feb. 4, 2021 /CNW/ - David Elsley, President & CEO, Cardiol
Therapeutics Inc. (TSX: CRDL), shares his company's story
in an interview with TMX Group.
The C-Suite at The Open video interview series highlights the
unique perspectives of listed companies on Toronto Stock Exchange
and TSX Venture Exchange. Videos provide insight into how
company executives think in the current business environment.
To see the latest C-Suite at The Open videos visit
https://www.tmxmoney.com/en/csuite.html.
About Cardiol Therapeutics Inc. (TSX: CRDL)
Cardiol Therapeutics Inc is a clinical-stage biotechnology
company developing therapies for inflammatory heart disease. The
company has received approval to commence a Phase II/III clinical
trial investigating its product, CardiolRx, in COVID-19 patients
with history of cardiovascular disease. CardiolRx is a
pharmaceutically produced, GMP certified, THC free (<10 ppm)
oral cannabidiol formulation. For more information visit:
https://www.cardiolrx.com/
About TMX Group (TSX: X)
TMX Group's key subsidiaries operate cash and derivative markets
and clearinghouses for multiple asset classes including equities
and fixed income. Toronto Stock Exchange, TSX Venture Exchange, TSX
Alpha Exchange, The Canadian Depository for Securities, Montréal
Exchange, Canadian Derivatives Clearing Corporation,
Trayport and other TMX Group companies provide listing
markets, trading markets, clearing facilities, depository services,
technology solutions, data products and other services to the
global financial community. TMX Group is headquartered in
Toronto and operates offices
across North America (Montréal,
Calgary, Vancouver and New
York), as well as in key international markets including
London, Beijing and Singapore. For more information about TMX
Group, visit our website at www.tmx.com. Follow TMX Group on
Twitter: @TMXGroup.
SOURCE TMX Group Limited